Another setback for Teva's ALS pipeline as talampanel tanks in Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva's selective AMPA antagonist talampanel failed to meet the primary endpoint in a Phase II trial in amyotrophic lateral sclerosis, ending its prospects. The May 17 announcement comes just over two years after Teva terminated its lead project in ALS, a higher-dose formulation of glatiramer, the active ingredient in Teva's multiple sclerosis therapy Copaxone, also after a Phase II failure (1"The Pink Sheet" DAILY, March 13, 2008). The Phase II ALSTAR trial of talampanel enrolled 559 ALS patients randomized to one of two doses of talampanel or placebo for 52 weeks to determine if the drug could reduce disease-related functional deterioration. Talampanel failed to show an effect on the change from baseline in the revised ALS Functional Rating Scale, the primary outcome measure, Teva reported, although the study did demonstrate the drug to be safe
You may also be interested in...
Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS
Compound fails to meet primary and secondary trial endpoints.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.